At a glance
- Originator Ajinomoto
- Class
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Transplant-rejection in Japan
- 16 Jan 2003 Preclinical trials in Transplant rejection in Japan (unspecified route)